Brokerages Set Sutro Biopharma, Inc. (NASDAQ:STRO) PT at $14.86

Sutro Biopharma, Inc. (NASDAQ:STRO) has been given an average recommendation of “Buy” by the seven research firms that are currently covering the company, MarketBeat.com reports. Seven analysts have rated the stock with a buy recommendation. The average 1-year price target among brokers that have issued a report on the stock in the last year is $13.71.

A number of analysts recently weighed in on STRO shares. Oppenheimer reissued an “outperform” rating and issued a $10.00 price target on shares of Sutro Biopharma in a report on Wednesday. JMP Securities restated a “market outperform” rating and set a $17.00 target price on shares of Sutro Biopharma in a research report on Tuesday. HC Wainwright decreased their price target on Sutro Biopharma from $16.00 to $12.00 and set a “buy” rating on the stock in a report on Tuesday. Finally, Wedbush dropped their price objective on Sutro Biopharma from $12.00 to $8.00 and set an “outperform” rating for the company in a report on Tuesday.

Insider Activity at Sutro Biopharma

In other Sutro Biopharma news, insider Nicki Vasquez sold 12,185 shares of the firm’s stock in a transaction dated Monday, January 29th. The stock was sold at an average price of $5.00, for a total transaction of $60,925.00. Following the transaction, the insider now owns 12,803 shares in the company, valued at $64,015. The sale was disclosed in a document filed with the SEC, which is available through this link. 6.90% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Sutro Biopharma

Several institutional investors and hedge funds have recently made changes to their positions in STRO. Vanguard Group Inc. lifted its holdings in Sutro Biopharma by 0.7% during the fourth quarter. Vanguard Group Inc. now owns 2,890,000 shares of the company’s stock worth $12,398,000 after acquiring an additional 21,238 shares in the last quarter. Virtu Financial LLC bought a new position in shares of Sutro Biopharma during the 4th quarter valued at about $72,000. Exome Asset Management LLC acquired a new position in shares of Sutro Biopharma in the 4th quarter valued at approximately $659,000. Barclays PLC increased its stake in Sutro Biopharma by 111.0% during the 4th quarter. Barclays PLC now owns 132,059 shares of the company’s stock worth $566,000 after purchasing an additional 69,480 shares in the last quarter. Finally, Nuveen Asset Management LLC raised its holdings in Sutro Biopharma by 1.7% during the 4th quarter. Nuveen Asset Management LLC now owns 215,728 shares of the company’s stock worth $925,000 after buying an additional 3,583 shares during the period. Institutional investors and hedge funds own 96.99% of the company’s stock.

Sutro Biopharma Stock Up 14.6 %

Shares of NASDAQ:STRO opened at $5.65 on Friday. Sutro Biopharma has a 12 month low of $2.01 and a 12 month high of $6.13. The firm has a market cap of $352.79 million, a P/E ratio of -3.17 and a beta of 0.95. The company’s 50-day moving average price is $4.53 and its two-hundred day moving average price is $3.79.

About Sutro Biopharma

Sutro Biopharma, Inc operates as a clinical-stage oncology company. It develops site-specific and novel-format antibody drug conjugates (ADC) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. The company's product candidates include STRO-001, an ADC directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials.